Carl Zeiss Meditec (ETR:AFX) PT Fixed at €170.00 by UBS Group


Carl Zeiss Meditec (ETR: AFXGet a rating) was given a target price of €170.00 ($178.95) by equity analysts at UBS Group in a research note released on Monday, Borsen Zeitung reports. UBS Group’s price target suggests upside potential of 45.74% from the stock’s previous close.

A number of other brokerages have also recently commented on AFX. HSBC set a price target of €146.00 ($153.68) on Carl Zeiss Meditec in a Monday, February 14 research report. Hauck and Aufhaeuser set a price target of €215.00 ($226.32) on Carl Zeiss Meditec in a Thursday, April 21 research report. Deutsche Bank Aktiengesellschaft set a €210.00 ($221.05) price target on Carl Zeiss Meditec in a Monday, February 14 research report. Finally, Deutsche Bank Rese… set a price target of €210.00 ($221.05) on Carl Zeiss Meditec in a research report on Monday.

AFX traded at €5.95 ($6.26) in midday trading on Monday, rising to €116.65 ($122.79). The company had a trading volume of 175,654 shares, compared to an average volume of 94,405. The company has a quick ratio of 2.90, a current ratio of 3.58 and a leverage ratio of 7.23. The company has a 50-day moving average of €133.53 and a two-hundred-day moving average of €151.85. The company has a market capitalization of $10.43 billion and a P/E ratio of 45.94. Carl Zeiss Meditec has a 1-year minimum of €104.75 ($110.26) and a 1-year maximum of €202.00 ($212.63).

About Carl Zeiss Meditec (Get a rating)

Carl Zeiss Meditec AG operates as a medical technology company in Germany, the rest of Europe, the USA, Asia and internationally. It operates through two segments, Ophthalmic Devices and Microsurgery. The Ophthalmic Devices segment offers products and solutions for the diagnosis and treatment of eye diseases; and systems and consumables for cataract, retina and refractive surgeries.

Read more



Get news and reviews for Carl Zeiss Meditec Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Carl Zeiss Meditec and related companies with MarketBeat.com’s free daily email newsletter.

Comments are closed.